Tradestie Institutional Equity Comparison Engine

SLN vs LCTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LCTX Overall Edge

LCTX Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin while SLN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, SLN trades at N/M Forward P/E with -11905.9% operating margin (+197.2% YoY revenue) versus LCTX at 30.7x Forward P/E and -280.3% operating margin (-61.0% YoY). In options structure, SLN sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro) against LCTX sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
SLN N/M vs LCTX 30.7x Fwd P/E
Growth & Margin Winner LCTX
Op Margin -11905.9% vs -280.3% ยท YoY +197.2% vs -61.0%
Momentum & Technical Winner SLN
1Y +208.1% vs -54.9% ยท 52W Pos 100% vs 0%
Options & Structure Winner SLN
UNCLASSIFIED (50th %ile IV) vs BREAKDOWN (<1st %ile IV)
SLN NASDAQ
Silence Therapeutics Plc American Depository Share
Pharmaceutical Preparations
$19.81
+0.0% 1D
Market Cap $1.2B
1M Return +0.76%
1Y Return +208.09%
Forward P/E N/M
Unified AI Score
45.6 / 100 HOLD
Tech 29.0 Fund 36.0 Flow 50.0 Mom 30.0
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
1M Return -21.63%
1Y Return -54.86%
Forward P/E 30.7x
Unified AI Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SLN +208.09% LCTX -54.86% Spread: +262.95 pp (SLN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SLN TTM Op. Margin: -11905.9% LCTX TTM Op. Margin: -280.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLN vs LCTX. Trailing 12-month operating profitability (SLN -11905.9% vs LCTX -280.3%) and valuation multiples (SLN N/M vs LCTX 30.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SLN (4) vs LCTX (6)
Institutional Metric SLN LCTX Criterion Row Winner
Market Capitalization Scale $1.2B $207.4M Larger Scale SLN
Trailing P/E Ratio Valuation N/M 30.7x Lower Multiple LCTX
Forward P/E Ratio Valuation N/M 30.7x Lower Multiple LCTX
Revenue Growth (YoY) Growth +197.2% -61.0% Higher Growth SLN
Operating Margin (TTM) Profitability -11905.9% -280.3% Higher Margin LCTX
Net Profit Margin Profitability 0.0% 16.2% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency -35.6% 4.3% Higher ROE LCTX
52-Week Range Position Momentum 100% ($4โ€“$20) 0% ($1โ€“$2) Stronger Trend SLN
Beta / 30D Volatility Risk Regime 1.77ฮฒ ยท 4% Vol 1.39ฮฒ ยท 79% Vol Lower Realized Risk SLN
Unified Institutional Score Composite Signal 45.6 / 100 (HOLD) 54.9 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SLN vs LCTX Buy Guide
SLN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live SLN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
7d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SLN nor LCTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.